Advertisement

 

 

Investigational protease inhibitors as antiretroviral therapies.

Investigational protease inhibitors as antiretroviral therapies.
Author Information (click to view)

Midde NM, Patters BJ, Rao P, Cory TJ, Kumar S,


Midde NM, Patters BJ, Rao P, Cory TJ, Kumar S, (click to view)

Midde NM, Patters BJ, Rao P, Cory TJ, Kumar S,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert opinion on investigational drugs 2016 7 14()

Abstract
INTRODUCTION
Highly Active Antiretroviral Therapy (HAART) has tremendously improved the life expectancy of the HIV-infected population over the past three decades. Protease inhibitors have been one of the major classes of drugs in HAART regimens that are effective in treating HIV. However, the emergence of resistance and cross-resistance against protease inhibitors encourages researchers to develop new PIs with broad-spectrum activity, as well as novel means of enhancing the efficacy of existing PIs.

AREAS COVERED
In this article we discuss recent advances in HIV protease inhibitor (PI) development, focusing on both investigational and experimental agents. We also include a section on pharmacokinetic booster drugs for improved bioavailability of protease inhibitors. Further, we discuss novel drug delivery systems using a variety of nanocarriers for the delivery of PIs across the blood-brain-barrier to treat the HIV in the brain.

EXPERT OPINION
We discuss our opinion on the promises and challenges on the development of novel investigational and experimental PIs that are less toxic and more effective in combating drug-resistance. Further, we discuss the future of novel nanocarriers that have been developed to deliver PIs to the brain cells. Although these are promising findings, many challenges need to be overcome prior to making them a viable option.

Submit a Comment

Your email address will not be published. Required fields are marked *

19 − two =

[ HIDE/SHOW ]